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projected using a peer-reviewed and validated computer simula-
tion model of diabetes. Clinical input (cohort characteristics and
treatment effects) were taken from PHAZIT, a prospective, non-
randomized, observational study of Type-2 diabetes patients
from 51 German diabetes centers. In PHAZIT, patients were
switched to a combination of IAsp/MET (n = 392) or HI/MET
(n = 353) at baseline. 24-week results showed an improvement
in HbA1c of 0.15% and decreased body mass index (BMI) (0.3
kg/m2) with IAsp/MET versus HI/MET. No signiﬁcant changes
in hypoglycemic event rates were observed. Transition probabil-
ities in the model and HbA1c-dependent adjustments were
derived from published sources. Direct costs were retrieved from
published data and accounted over patient lifetimes. Costs and
clinical beneﬁts were discounted at 3.5% annually. RESULTS:
Long-term projections showed that IAsp/MET treatment was
associated with fewer diabetes-related complications, improved
life expectancy (0.13 life years gained) and quality-adjusted life
expectancy (0.09 QALYs gained) compared to HI/MET. Mean
total lifetime costs were €1,173 per patient higher with
IAsp/MET, leading to incremental cost-effectiveness ratios
(ICERs) of €9,023 per life year gained and €13,033 per QALY
gained. CONCLUSIONS: Based on data from the 24-week
PHAZIT trial, improvements in glycemic control and BMI asso-
ciated with IAsp/MET were projected to lead to fewer diabetes-
related complications, as well as improved life expectancy and
quality-adjusted life expectancy compared to HI/MET. Incre-
mental cost-effectiveness analysis indicated that IAsp/MET was
within range taken to represent good value for money compared
to HI/MET in the treatment of Type-2 diabetes over patient life-
times in the German setting.
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OBJECTIVES: To evaluate the cost-effectiveness of oral anti-
diabetic therapies, a ﬁxed combination (metformin plus
glibenglamide, Glucovance®) and a free combination (metformin
plus rosiglitazone), in France. METHODS: A peer-reviewed,
published, validated computer simulation model was used to
project long-term clinical and cost outcomes of treatment with
Glucovance® or metformin + rosiglitazone. The model combined
standard Markov sub-models to simulate the incidence and pro-
gression of complications and calculate costs over patients’ life-
times. Transition probabilities and risk adjustments were derived
from published sources, including the UKPDS. Treatment effects,
average doses and baseline cohort characteristics were taken
from a recent double-blind randomized clinical trial showing
that Glucovance® resulted in signiﬁcantly greater reductions in
HbA1c (-0.4%) compared with metformin + rosiglitazone in
Type-2 diabetes patients inadequately controlled on metformin
monotherapy. Direct costs (2004 Euros) were retrieved from
published sources and projected over patient lifetimes from a
third party health care payer perspective. Costs and clinical ben-
eﬁts were discounted at 3% annually. RESULTS: In the long-
term, Glucovance® treatment was associated with improvements
in discounted life expectancy (0.19 years) and quality-adjusted
life expectancy (0.18 years) compared to metformin + rosiglita-
zone. Undiscounted life expectancies were 14.73 and 14.40 years
in the Glucovance® and metformin + rosiglitazone groups respec-
tively. Diabetes-related complications were delayed by an
average of 0.3 years in the Glucovance® arm. Lifetime direct
costs (treatment and complication costs) were on average less
expensive with Glucovance® than with metformin + rosiglitazone
(by €5605 per patient). At a shorter time horizon of 10 years,
Glucovance® treatment was also projected to be associated with
improved life expectancy and lower total costs than metformin
+ rosiglitazone. CONCLUSIONS: In France, Glucovance® is
dominant to metformin + rosiglitazone over medium and long-
term time horizons, leading to improvements in life expectancy,
quality-adjusted life expectancy and cost savings in Type-2 
diabetes patients inadequately controlled on metformin
monotherapy.
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OBJECTIVES: To project the long-term clinical and economic
outcomes of intensive treatment with either biphasic insulin
aspart 30 (BIAsp30) or insulin glargine among Type-2 diabetes
patients exhibiting particularly high HbA1c levels when taking
oral antidiabetic therapy alone. METHODS: Baseline character-
istics and end-of-study treatment effect data among a sub-pop-
ulation of insulin naïve Type-2 subjects with baseline HbA1c
levels ≥ 8.5% (mean HbA1c: 10.2%) were derived from a mul-
ticenter, 28-week, head-to-head clinical trial (INITIATE). Signif-
icant improvements in HbA1c levels favoring randomization to
twice-daily BIAsp 30 + metformin (met) ± thiazolidinedione
(TZD) compared to bedtime insulin glargine + met ± TZD were
demonstrated (-0.53% between arms; p < 0.005). A peer-
reviewed, validated Markov/Monte-Carlo model combining
published literature for risk of long-term diabetic complications
with quality-of-life utilities projected the incremental cost-effec-
tiveness ratio (ICER) and cumulative incidences of diabetes-
related complications over 35 years. Cost-effectiveness was
measured as cost per life years gained (LYG) and cost per quality
adjusted life years gained (QALY). Cardiovascular, neurological,
renal, and retinal complication rates were assessed. Lifetime
costs were calculated as the annual direct pharmacy costs plus
complication costs (US Medicare perspective). Clinical outcomes
and costs were discounted at 3% annually. Sensitivity analyses
were performed. RESULTS: Improvements in glycemic control
corresponded with incremental increases in LYG and QALY
favoring BIAsp 30 versus glargine (0.28 ± 0.21 and 0.27 ± 0.15
years, respectively). Treatment with BIAsp 30 was associated
with reductions in the cumulative incidence of diabetes-related
complications, notably in renal (18% less end-stage renal
disease) and retinal (12% less severe vision loss) co-morbidities.
An ICER of $30,924 per QALY gained was deduced. Sensitivity
analyses support the reliability of the results. CONCLUSIONS:
Among a sub-population of poorly controlled insulin naïve Type-
2 patients, BIAsp 30 was estimated to reduce lifetime complica-
tion incidences and be cost-effective within commonly supported
thresholds when compared to insulin glargine.
